Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Ocaliva-related Liver Injury Warnings Will be Added to Ocaliva Drug Label

June 1, 2021 By Law Offices of Thomas J. Lamb, P.A.

We now know more about the Ocaliva-related liver injury “safety signal” that the FDA has been investigating over the past year, and as a result of that Ocaliva FDA safety evaluation there will be an Ocaliva label change with new warnings. On May 26, 2021, this FDA Drug Safety Communication about Ocaliva, “Due to risk of serious liver injury, FDA … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug-induced liver injury, liver damage, liver failure, liver injury, liver transplants, Ocaliva

Ocaliva Drug Label Warnings vis-à-vis FDA Ocaliva Safety Signal Investigation

October 19, 2020 By Law Offices of Thomas J. Lamb, P.A.

In our last article, we reported on the current FDA investigation of an Ocaliva safety signal which, although it began in May 2020, only became public knowledge in October. The best we can tell, it is a possible Ocaliva liver toxicity issue that is the subject of this Ocaliva FDA investigation. Now we have some additional information about some … [Read more...]

Filed Under: Unsafe Drugs Tagged With: liver damage, liver failure, liver injury, Ocaliva

Current Ocaliva Liver Safety FDA Evaluation Started Back in May 2020

October 15, 2020 By Law Offices of Thomas J. Lamb, P.A.

In October 2020 we first learned about a "new" drug safety issue for Ocaliva -- although it apparently has been on the FDA's radar since at least May 2020. It seems a possible Ocaliva liver-related side effects risk has attracted scrutiny, and there is an Ocaliva liver safety FDA evaluation underway. It was this October 9, 2020, Endpoints News … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug-induced liver injury, liver damage, liver failure, liver injury, Ocaliva

Lemtrada Safety Issues Lead To Use Restrictions In Europe

November 26, 2019 By Law Offices of Thomas J. Lamb, P.A.

Drug safety regulators for the European Union recently recommended that Lemtrada use be restricted to certain limited patient populations due to serious side effects linked to Lemtrada. This November 5, 2019 Multiple Sclerosis News Today report, “EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals … [Read more...]

Filed Under: Unsafe Drugs Tagged With: bleeding disorders, bleeding in the lungs, Heart Attacks, Hepatitis, Lemtrada, liver damage, Strokes

Actemra Drug-Induced Liver Injuries Warning From Health Canada

May 29, 2019 By Law Offices of Thomas J. Lamb, P.A.

Actemra drug-induced liver injuries, which can be serious, life-threatening, or even fatal. This is according the Canadian drug regulatory agency, Health Canada, which issued this Dear Healthcare Professional Letter, “Important Safety Information on ACTEMRA ® (tocilizumab) – Risk of Hepatotoxicity”, on May 21, 2019. From this Health Canada … [Read more...]

Filed Under: Uncategorized, Unsafe Drugs Tagged With: Actemra, drug-induced liver injury, liver damage, liver failure, liver transplants

Lemtrada Side Effects Being Investigated By European Drug Regulatory Agency

April 29, 2019 By Law Offices of Thomas J. Lamb, P.A.

The multiple sclerosis drug Lemtrada (alemtuzumab) is under scrutiny from the European Medicines Agency (EMA), according to the drug regulator’s April 12, 2019 press release, “Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing”. From this April 14, 2019 Medscape article, “PRAC Restricts Use of Alemtuzumab for MS … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cardiovascular events, Lemtrada, liver damage, pulmonary side effects

Pradaxa Liver Injury: Label Changes Warning About This Increased Risk

July 27, 2018 By Law Offices of Thomas J. Lamb, P.A.

We are watching to see whether the FDA and/or European drug regulators require a Pradaxa liver injury label change adding a new warning about an increased risk of acute liver failure and drug-induced hepatitis — like what was done in Japan last year and is being done now in Canada. In May 2018 Health Canada announced that their Pradaxa drug … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug side effects, drug-induced liver injury, liver damage, liver failure, liver injury, Pradaxa

Ocaliva Patients Died From Liver Injury Says September 2017 FDA Report

October 5, 2017 By Law Offices of Thomas J. Lamb, P.A.

A liver side effects issue for Ocaliva was presented in this document, “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic chronic liver disease”, issued on September 21, 2017. From the Safety Announcement part of that document: The Food and Drug Administration (FDA) is warning … [Read more...]

Filed Under: Unsafe Drugs Tagged With: liver damage, liver failure, liver injury, Ocaliva

Warnings About Significant Liver Injury Added To Tecfidera Drug Label

February 10, 2017 By Law Offices of Thomas J. Lamb, P.A.

In January 2017 liver injury was added to the Warnings and Precautions part of the Prescribing Information document, or drug label, for Tecfidera (dimethyl fumarate), which was approved by the FDA in 2013 as a treatment of patients with relapsing forms of multiple sclerosis (MS). We get background information and some commentary from this … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug injury, drug side effects, Hepatitis, Hepatotoxicity, liver damage, liver injury, Tecfidera

Safety of Hepatitis C Treatment Drugs Called Into Question

January 30, 2017 By Law Offices of Thomas J. Lamb, P.A.

UPDATE:  On February 14, 2017, the FDA released a Black Box warning for these drugs with the following text:Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death.(2/16/17).Recently, the safety of the newer hepatitis C treatment drugs -- such as Solvadi and Harvoni -- is … [Read more...]

Filed Under: Uncategorized Tagged With: daclatasvir, Daklinza, dasabuvir, direct-acting antiviral drugs, drug injury, drug side effects, elbasvir, Epclusa, grazoprevir, Harvoni, hepatitis b reactivation, hepatitis c treatment drugs, Institute for Safe Medication Practices, lawsuits, ledipasvir, liver damage, liver failure, liver injury, Olysio, ombitasvir, paritaprevir, ritonavir, simeprevir, sofosbuvir, Sovaldi, Technivie, velpatasvir, Viekira Pak, Zepatier

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.